AU2017213812B2 - Mesenchymal stem cells as vaccine adjuvants and methods for using the same - Google Patents

Mesenchymal stem cells as vaccine adjuvants and methods for using the same Download PDF

Info

Publication number
AU2017213812B2
AU2017213812B2 AU2017213812A AU2017213812A AU2017213812B2 AU 2017213812 B2 AU2017213812 B2 AU 2017213812B2 AU 2017213812 A AU2017213812 A AU 2017213812A AU 2017213812 A AU2017213812 A AU 2017213812A AU 2017213812 B2 AU2017213812 B2 AU 2017213812B2
Authority
AU
Australia
Prior art keywords
adjuvant
vaccine
subject
administered
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017213812A
Other languages
English (en)
Other versions
AU2017213812A1 (en
Inventor
Joshua M. Hare
Ana Marie LANDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of AU2017213812A1 publication Critical patent/AU2017213812A1/en
Assigned to LONGEVERON INC. reassignment LONGEVERON INC. Amend patent request/document other than specification (104) Assignors: LONGEVERON LLC
Application granted granted Critical
Publication of AU2017213812B2 publication Critical patent/AU2017213812B2/en
Priority to AU2024204598A priority Critical patent/AU2024204598A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017213812A 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same Active AU2017213812B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204598A AU2024204598A1 (en) 2016-02-04 2024-07-03 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291350P 2016-02-04 2016-02-04
US62/291,350 2016-02-04
PCT/US2017/016200 WO2017136539A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204598A Division AU2024204598A1 (en) 2016-02-04 2024-07-03 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Publications (2)

Publication Number Publication Date
AU2017213812A1 AU2017213812A1 (en) 2018-08-16
AU2017213812B2 true AU2017213812B2 (en) 2024-04-04

Family

ID=58261704

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017213812A Active AU2017213812B2 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same
AU2024204598A Pending AU2024204598A1 (en) 2016-02-04 2024-07-03 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204598A Pending AU2024204598A1 (en) 2016-02-04 2024-07-03 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Country Status (11)

Country Link
US (2) US11975068B2 (https=)
EP (2) EP4316497A3 (https=)
JP (3) JP7814090B2 (https=)
KR (1) KR20180105705A (https=)
AU (2) AU2017213812B2 (https=)
CA (1) CA3013457A1 (https=)
ES (1) ES2960206T3 (https=)
IL (1) IL260858B (https=)
SG (1) SG11201806587RA (https=)
WO (1) WO2017136539A1 (https=)
ZA (2) ZA201805159B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020166063A1 (ja) * 2019-02-15 2020-08-20 大和薬品株式会社 フレイル改善方法およびフレイル改善食品
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
JP2023540096A (ja) 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗
US20220218817A1 (en) * 2021-01-08 2022-07-14 Vitro Biopharma, Inc. Immune modulation by mesenchymal stem cells
CN117999082A (zh) 2021-07-26 2024-05-07 美商生命科学有限公司 间充质干细胞在治疗青少年左心发育不良综合征中的用途
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US8554280B2 (en) 2010-03-23 2013-10-08 Ebay Inc. Free-form entries during payment processes
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN104138391B (zh) 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUZANNE L. TOMCHUCK ET AL, FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, vol. 2, 16 November 2002 (2002-11-16), pages 1 - 8, DOI: 10.3389/fcimb.2012.00140 *

Also Published As

Publication number Publication date
CA3013457A1 (en) 2017-08-10
JP2026012755A (ja) 2026-01-27
JP2023036949A (ja) 2023-03-14
EP3411050B1 (en) 2023-09-27
WO2017136539A1 (en) 2017-08-10
SG11201806587RA (en) 2018-09-27
EP4316497A2 (en) 2024-02-07
JP2019509264A (ja) 2019-04-04
ES2960206T3 (es) 2024-03-01
US20190038742A1 (en) 2019-02-07
AU2024204598A1 (en) 2024-07-18
ZA202000574B (en) 2021-08-25
EP3411050A1 (en) 2018-12-12
ZA201805159B (en) 2020-10-28
EP4316497A3 (en) 2024-05-01
US11975068B2 (en) 2024-05-07
IL260858B (en) 2022-04-01
AU2017213812A1 (en) 2018-08-16
IL260858A (en) 2018-10-31
US20240252627A1 (en) 2024-08-01
KR20180105705A (ko) 2018-09-28
JP7814090B2 (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
US20240252627A1 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
US20260027158A1 (en) Methods of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity
KR101788885B1 (ko) 세포 요법에 사용하기 위한 방법 및 조성물
ES2987001T3 (es) Tratamiento de la caquexia usando células de fibroblasto y productos de las mismas
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
US20260000669A1 (en) Treatment regimen for autoimmune diseases and inflammatory diseases
Russell Inducing IL-1β to increase vaccine efficacy
NZ794290A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
NZ794292A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LONGEVERON INC.

Free format text: FORMER NAME(S): LONGEVERON LLC

FGA Letters patent sealed or granted (standard patent)